Member Profile

Owner of a proprietary cell expansion technique, Taiwan-Bio has been dedicated to the development of human mesenchymal stem cell products and the clinical application of such cell therapy products to the treatment of cardiovascular, orthopedic diseases, inflammatory diseases. So far, our most advanced innovative MSCs therapeutic agent Biochymal® for lower limb ischemia has completed a phase I/IIa trial. Our second product Chondrochymal® has also completed a phase I/IIa trial for treatment of knee osteoarthritis and are now entering phase IIb stage. In addition to substantiating the development of our current cell therapy products, a several more potent second and third generation cell therapy products are also being developed at the preclinical stage. Importantly, Taiwan-Bio is also the owner of a state-of-the-art PIC/S GMP Cell Processing Center, allowing us to provide cell therapy product CMO and CDMO services for our clients.